10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TSG101 Antibody

Purified Mouse Monoclonal Antibody (Mab)
Catalog # AM8662b

Product Information

Application	WB, E
Primary Accession	Q99816
Reactivity	Human
Predicted	Mouse, Rat, Bovine, Canine, Rabbit, Chicken
Host	Mouse
Clonality	monoclonal
Isotype	IgG1,κ
Clone Names	1883CT788.47.15.46
Calculated MW	43944

Additional Information

Gene ID	7251
Other Names	Tumor susceptibility gene 101 protein, ESCRT-I complex subunit TSG101, TSG101
Target/Specificity	This antibody is generated from a mouse immunized with a recombinant protein from human.
Dilution	WB~~1:2000 E~~Use at an assay dependent concentration.
Format	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	TSG101 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	TSG101
Function	Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in

	cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413). It may also play a role in the extracellular release of microvesicles that differ from the exosomes (PubMed:22315426).
Cellular Location	Cytoplasm. Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Late endosome membrane; Peripheral membrane protein. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Midbody, Midbody ring. Nucleus. Note=Mainly cytoplasmic. Membrane-associated when active and soluble when inactive. Nuclear localization is cell cycle-dependent. Interaction with CEP55 is required for localization to the midbody during cytokinesis
Tissue Location	Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas


Background

Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses.

References

Li L.,et al.Cell 88:143-154(1997).
Li L.,et al.Cell 93:661-661(1998).
Gayther S.A.,et al.Oncogene 15:2119-2126(1997).
Lee M.P.,et al.Cancer Res. 57:3131-3134(1997).
Wagner K.-U.,et al.Oncogene 17:2761-2770(1998).

Images



All lanes: Anti-TSG101 Antibody at 1:1000 dilution Lane 1: K562 whole cell lysate Lane 2: Jurkat whole cell lysate Lane 3: HepG2 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Mouse IgG, (H+L), Peroxidase conjugated (ASP1613) at 1/8000 dilution. Observed band size: 44 KDa Blocking/Dilution buffer: 5% NFDM/TBST.

Citations

- A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective

Multicenter Diagnostic Feasibility Study

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.